We here investigated changes in the tumour-immune microenvironment following treatment with lapatinib and trastuzumab and the relationship of sTILs with HR status, intrinsic subtype and immune-related gene expression in patients with HER2+ BC from the PAMELA trial. Here, ERBB2 is linked to neoplasm.